Rules & thesis
Resolution order: macro thesis → general category rules → company-specific rules (win on conflict) → your Level-3 manual overrides (always win). Claude may draft rule revisions; you approve.
Macro assumptions
CAPM cost of equity = risk-free + β × ERP. The GDP ceiling hard-caps DCF terminal growth. Category β is the default; a company rule can override it.
RadTech
synthesized · Jul 23, 2026RadTech companies face a cautious near-term outlook, with management at both MIR and ARAY citing macroeconomic risks from tariffs and supply chain disruptions. While MIR benefits from nuclear energy tailwinds and ARAY faces hospital capital budget constraints, both emphasize uncertainty in their operating environments and have updated risk factors to reflect trade and supply chain risks. The overall tone is one of tempered optimism, with a focus on navigating external headwinds.
MedTech
synthesized · Jul 23, 2026ISRG's forward-looking content highlights a focus on synthesizing scientific and technological advances to deliver value through the Quintuple Aim, emphasizing better outcomes, experience, access, and cost reduction. The company's strategic priorities center on providing clinical and economical solutions across procedure complexity and focusing on high-value procedures. Since only ISRG's content is available, this thesis is company-specific and cannot be generalized across the MedTech category.
Pharma
synthesized · Jul 23, 2026Moderna is transitioning from pandemic-driven demand to an endemic and pipeline-dependent model, focusing on revenue growth through geographic expansion and new launches, cost discipline, and pipeline execution despite near-term losses. This outlook is company-specific and not corroborated by other companies in the category.
Rule-change proposals
- rule-book-to-billJul 18, 2026Current
Flag when book-to-bill falls below 1.0. Escalate on a second consecutive quarter below 1.0.
ProposedFlag when book-to-bill falls below 1.0 AND backlog declines sequentially. A sub-1.0 quarter with rising backlog is timing, not deterioration, and should stay at 'watch' rather than escalate.
ReasoningReview of the last two ARAY escalations: both sub-1.0 quarters were followed by in-line revenue because backlog held. The rule over-escalated on timing noise. Adding the backlog condition would have kept both at 'watch' and avoided two false-elevated flags.
Triggered by: Position review after ARAY flag did not translate into a revenue miss.
Leverage discipline
allv3Flag when net leverage exceeds 2.5x. Escalate above 3.5x or when a refinancing falls inside 12 months.
- ARAYNet leverage estimated at ~6.2x, far exceeding the 2.5x threshold and the 3.5x escalation point. Covenant compliance risk persists.
Last updated Jul 22, 2026
Order momentum
RadTechv2Flag when book-to-bill falls below 1.0. Escalate on a second consecutive quarter below 1.0.
Last updated Jul 22, 2026
Revenue concentration
allv4Flag when a single product or customer exceeds 40% of revenue, or when a credible competitive threat targets that concentration.
- MRNARevenue is concentrated in COVID vaccine products (primarily mNEXSPIKE and predecessor), exceeding 40% of total revenue. Competitive threats from updated mRNA vaccines and other platforms could impact market share.
Last updated Jul 22, 2026
Cash runway (pre-revenue)
Pharmav1For pre-revenue names, flag when estimated cash runway is under 24 months ahead of a value-inflection readout.
Last updated Jul 22, 2026
Customer capex cycle
MedTechv1Flag when leading indicators of customer capex (research/biopharma funding) turn negative for two consecutive periods.
Last updated Jul 22, 2026
New filing
allv1Raise an informational flag whenever a new EDGAR filing is detected and ingested.
- ARAYNew 10-Q filing detected: Q3 fiscal 2026 results showing net loss of $11.8M, negative operating cash flow, and debt of $145.2M net.
- ARAYNew 10-K/A filing detected: Fiscal 2025 results with RPO restatement and material weakness.
- ARAYNew 8-K filing detected: Accuray repaid remaining $18.0M of 3.75% Convertible Senior Notes at maturity on June 1, 2026.
- ARAYNew 10-Q filing detected: Q2 fiscal 2026 results showing revenue decline, net loss of $13.8M, and restructuring charges.
- MIRNew 8-K filed July 2, 2026, regarding compensatory arrangement with President of Nuclear & Safety Group.
- MIRNew 10-Q for Q1 2026 filed, detailing financial results and risks.
- ISRGNew EDGAR filings detected and ingested: 10-Q for Q1 2026, 10-Q for Q2 2026, and 10-K for fiscal year 2025.
- MRNANew EDGAR filings detected and ingested: 2025 10-K, Q3 2025 10-Q, Q1 2026 10-Q, and 8-K (May 1, 2026).
Last updated Jul 22, 2026
Balance-sheet distress
allreliabilityv1Flag Stage 1 as unreliable when net leverage is high AND margins are thin or negative — the mechanical peer multiple overstates fair value for distressed names. Present a distressed range, not a single number.
- ARAYBalance-sheet distress flagged: high net leverage combined with negative net income and thin margins. Stage 1 peer multiple is unreliable; present a distressed range.
- MIRNet leverage is high (substantial debt) and margins are thin/negative (Q1 net loss of $3.4M), suggesting Stage 1 peer multiple overstates fair value. A distressed valuation range should be applied instead of a single point estimate.
Last updated Jul 22, 2026
ARAY balance-sheet distress
RadTechARAYreliabilityv1ARAY carries ~6.2x net leverage on thin, negative-net-income results. Treat the Stage 1 baseline as distress-flagged with a haircut range; the peer EV/EBITDA multiple is not a reliable point estimate here.
- ARAYARAY-specific distress: 6.2x net leverage and negative net income. Treat Stage 1 baseline as distress-flagged; the peer EV/EBITDA multiple is not a reliable point estimate.
Last updated Jul 22, 2026
ISRG durable compounder
MedTechISRGv1ISRG compounds revenue ~20%/yr with a long robotic-surgery penetration runway. Use the full 10-year explicit horizon and a terminal growth at the GDP ceiling, rather than fading its growth to the terminal rate inside the generic window.
Last updated Jul 30, 2026